FDA approves Kremer Excimer laser for LASIK treatment

17 Jun 2002

The U.S. Food and Drug Administration has given premarket approval to LaserSight Incorporated for the Kremer Excimer Laser to perform Laser In-Situ Keratomileuisis (LASIK) for correction of myopia and myopic astigmatism. The approval is for a single device and requires supplemental manufacturing approval by the FDA to manufacture or distribute additional lasers, and is for LASIK, using a 6 millimeter ablation zone, to treat myopia from -1.0 to -15.0 diopters with or without astigmatism ranging from 0.0 to 5.0 diopters.